Summary
CVS Health Corporation (then CVS Caremark) announced on November 26, 2013, a significant definitive agreement to acquire Coram LLC, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. This acquisition, valued at approximately $2.1 billion, represents a strategic move to expand CVS's presence in the high-growth specialty pharmacy and home healthcare sector. The deal involves the purchase of all outstanding shares of the target company and the repayment of certain indebtedness, positioning CVS to strengthen its capabilities in managing complex patient needs and chronic conditions. Investors should note that this acquisition is subject to customary closing conditions, including regulatory approvals (such as antitrust) and the completion of specific restructuring steps by the seller. The financial impact and detailed integration plans are expected to unfold following the closure of the transaction. This move underscores CVS's ongoing strategy of consolidating and enhancing its healthcare services offerings to drive long-term growth and competitive advantage.
Key Highlights
- 1CVS Caremark to acquire Coram LLC, a specialty infusion services and enteral nutrition business, for approximately $2.1 billion.
- 2The acquisition aims to bolster CVS's specialty pharmacy and home healthcare capabilities.
- 3The deal involves the purchase of all issued and outstanding common shares of Coram LLC and repayment of certain indebtedness.
- 4Transaction is subject to regulatory approvals, including antitrust clearance.
- 5Completion of certain restructuring steps by the seller is a prerequisite for closing.
- 6The Stock Purchase Agreement outlines the terms and conditions of the acquisition between CVS Caremark and Apria Healthcare Group Inc.